Literature DB >> 3073045

Ceftriaxone in the treatment of bacterial meningitis in adults.

I Zavala1, E Barrera, A Nava.   

Abstract

Twenty-six adults with acute bacterial meningitis were enrolled in an open randomized comparative study. The organisms isolated from CSF were Streptococcus pneumoniae, Staphylococcus epidermidis, Haemophilus influenzae, Escherichia coli and Salmonella typhi. 13 patients (group A) were treated once daily with intravenous ceftriaxone (Rocephin). The 13 patients in group B received ampicillin or ampicillin plus chloramphenicol in 4 doses/day. The mean duration of therapy in groups A and B was 9.9 and 12.3 days, respectively. This difference in the duration of therapy was statistically significant. All patients from group A showed clinical improvement and all were bacteriologically cured. In group B only 12 patients were clinically and bacteriologically cured; 1 patient had to be withdrawn from the therapy because CSF culture remained positive after 48 h of therapy. Ceftriaxone was well tolerated in all patients; ampicillin or ampicillin plus chloramphenicol were associated with diarrhea and skin rash in 6 patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3073045     DOI: 10.1159/000238647

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

Review 1.  Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis.

Authors:  K Prasad; A Kumar; P K Gupta; T Singhal
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

2.  Salmonella meningitis in an adult with type B viral hepatitis and an incidental schwannoma.

Authors:  Fuad Khalil Al-Aani; Salem Abusalah; Rafid Al-Aqeedi; Abdulsalam Ibrahim
Journal:  BMJ Case Rep       Date:  2009-05-18

3.  Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults.

Authors:  K Marhoum el Filali; M Noun; A Chakib; M Zahraoui; H Himmich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.